Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi for full rights to the pair of antibody programs for use against eye diseases.
WIth Sanofi riding the tail end of the latest earnings wave, its sales and profits shortfall feels like more of the same. It hasn't been a good quarter for Big Pharma, and Sanofi's results fall right in line with the rest. Its 5.3% sales drop was less severe than most, while its profits suffered a bit more, with a 34% decline.
The company said it is no longer employing Daniel Vial, who has been caught up in the probe of the offshore bank account of former Budget Minister Jerome Cahuzac.
Sanofi CEO Chris Viehbacher says the French drugmaker is not interested in pursuing Alzheimer's drugs until the science of the disease is better understood.
Count Sanofi out of the wild chase to develop Alzheimer's drugs, at least while the best line of attack against the memory-robbing disease remains unclear. Sanofi CEO Chris Viehbacher revealed his desire to avoid costly clinical trials for AD drugs in an interview with Bloomberg , hinting that the passionate pursuit of such therapies lacks a deep understanding of disease biology.
Sanofi CEO Chris Viehbacher has been openly critical of his research operation in Toulouse, France. He said the researchers are costing too much money and haven't developed an important drug in 20 years.
Last year Sanofi boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.
Sanofi wants to expand into the diagnostics space, CEO Chris Viehbacher disclosed in a recent Bloomberg interview.
If you think Sanofi CEO Chris Viehbacher is done diversifying, think again. At a time when other companies are chucking "ancillary" units to zero in on their core drug-making businesses, Viehbacher wants to do just the opposite.
Where would Sanofi be without Lantus? The diabetes drug just keeps on churning up sales growth, quarter after quarter. In the fourth quarter, Lantus products grew by more than 22% to €1.33 billion. For the full year, the drug racked up almost €5 billion.